These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 32513867)

  • 21. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
    Wang W; Wang H; Deng Y; Song T; Lan J; Wu G; Ke C; Tan W
    Emerg Microbes Infect; 2016 Nov; 5(11):e113. PubMed ID: 27826140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
    Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X
    Front Immunol; 2021; 12():724763. PubMed ID: 34489978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study.
    Horn MP; Jonsdottir HR; Brigger D; Damonti L; Suter-Riniker F; Endrich O; Froehlich TK; Fiedler M; Largiadèr CR; Marschall J; Weber B; Eggel A; Nagler M
    Allergy; 2022 Jul; 77(7):2090-2103. PubMed ID: 34986501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing Antibodies.
    Li C; Li W; Lucio de Esesarte E; Guo H; van den Elzen P; Aarts E; van den Born E; Rottier PJM; Bosch BJ
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.
    Okba NMA; Widjaja I; van Dieren B; Aebischer A; van Amerongen G; de Waal L; Stittelaar KJ; Schipper D; Martina B; van den Brand JMA; Beer M; Bosch BJ; Haagmans BL
    Emerg Microbes Infect; 2020 Dec; 9(1):1080-1091. PubMed ID: 32471334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.
    Wang C; Hua C; Xia S; Li W; Lu L; Jiang S
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination.
    Chen Y; Zhu L; Huang W; Tong X; Wu H; Tao Y; Tong B; Huang H; Chen J; Zhao X; Lou Y; Wu C
    Emerg Microbes Infect; 2021 Dec; 10(1):1390-1403. PubMed ID: 34120577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
    Niu L; Wittrock KN; Clabaugh GC; Srivastava V; Cho MW
    Front Immunol; 2021; 12():647934. PubMed ID: 33995366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors.
    Phakaratsakul S; Manopwisedjaroen S; Boonarkart C; Kupatawintu P; Chaiwanichsiri D; Roytrakul T; Auewarakul P; Thitithanyanont A
    Viral Immunol; 2022 Oct; 35(8):545-552. PubMed ID: 36190505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.
    Dickey TH; Salinas ND; Patel P; Orr-Gonzalez S; Ouahes T; McAleese H; Richardson BL; Singleton M; Murphy M; Eaton B; Kwan JL; Holbrook MR; Lambert LE; Tolia NH
    Antiviral Res; 2024 Aug; 228():105937. PubMed ID: 38901738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.
    Hattori T; Koide A; Noval MG; Panchenko T; Romero LA; Teng KW; Tada T; Landau NR; Stapleford KA; Koide S
    J Mol Biol; 2021 Feb; 433(3):166748. PubMed ID: 33310017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.
    Jiang M; Zhang G; Liu H; Ding P; Liu Y; Tian Y; Wang Y; Wang A
    Front Immunol; 2021; 12():707977. PubMed ID: 34621266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immunodominant and neutralization linear epitopes for SARS-CoV-2.
    Lu S; Xie XX; Zhao L; Wang B; Zhu J; Yang TR; Yang GW; Ji M; Lv CP; Xue J; Dai EH; Fu XM; Liu DQ; Zhang L; Hou SJ; Yu XL; Wang YL; Gao HX; Shi XH; Ke CW; Ke BX; Jiang CG; Liu RT
    Cell Rep; 2021 Jan; 34(4):108666. PubMed ID: 33503420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
    Huang WC; Zhou S; He X; Chiem K; Mabrouk MT; Nissly RH; Bird IM; Strauss M; Sambhara S; Ortega J; Wohlfert EA; Martinez-Sobrido L; Kuchipudi SV; Davidson BA; Lovell JF
    Adv Mater; 2020 Dec; 32(50):e2005637. PubMed ID: 33111375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.
    He Y; Zhou Y; Liu S; Kou Z; Li W; Farzan M; Jiang S
    Biochem Biophys Res Commun; 2004 Nov; 324(2):773-81. PubMed ID: 15474494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of monoclonal antibodies targeting SARS-CoV-2 spike glycoprotein: Reactivity against Delta and Omicron BA.1 variants.
    Kulkarni PM; Basagoudanavar SH; Gopinath S; Patangia H; Gupta PK; Sreenivasa BP; Senthilkumar D; Sharma R; Bhatia S; Sharma GK; Bhanuprakash V; Saikumar G; Yadav P; Singh RK; Sanyal A; Hosamani M
    J Virol Methods; 2024 Dec; 330():115027. PubMed ID: 39216601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants.
    Schön J; Aebischer A; Halwe NJ; Ulrich L; Hoffmann D; Reiche S; Beer M; Grund C
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.
    Secchi M; Bazzigaluppi E; Brigatti C; Marzinotto I; Tresoldi C; Rovere-Querini P; Poli A; Castagna A; Scarlatti G; Zangrillo A; Ciceri F; Piemonti L; Lampasona V
    J Clin Invest; 2020 Dec; 130(12):6366-6378. PubMed ID: 32991329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.